Skip to content
Acrisorcin
Akrinol (acrisorcin) is a small molecule pharmaceutical. Acrisorcin was first approved as Akrinol on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acrisorcin
Tradename
Company
Number
Date
Products
AKRINOLMerck Sharp & DohmeN-012470 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameACRISORCIN
INNacrisorcin
Description
Acrisorcin is a topical anti-infective typically used as a fungicide. It is a combination of the active ingredients 9-aminoacridine and 4-hexylresorcinol.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCc1ccc(O)cc1O.Nc1c2ccccc2nc2ccccc12
Identifiers
PDB—
CAS-ID7527-91-5
RxCUI—
ChEMBL IDCHEMBL1201038
ChEBI ID—
PubChem CID24144
DrugBank—
UNII ID2U918O4BEV (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 18 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details